Big deal. If I were he I would step down before the company goes public again. He’s no spring chicken and he has other business interests. Being a director of a public company is a highly onerous business unless you treat the responsibilities like a vaudeville clown. Does that make anyone else think of Desperate Dan?
Mike Flaa will remain a substantial shareholder and if he feels confident to leave the decisions in the hands of others then why should we feel any less confident? Thanks, Mike and good luck with whatever else you are doing.
I will not be at all surprised if other directors choose to step down and some new faces, but experienced biotech hands, replace them. It will be additional good news.
Market Data 
Markets 
AI
